Who, and what, gets trusted with the next decade of drug discovery. The answers, so far: an AI résumé, and in China, a shrug.
GSK spends $10.6bn to outrun a patent cliff while the Pentagon quietly reprices the supply chain underneath everyone. Two different bets on the same question: what is access actually worth.
ASCO ended a week ago. The filing and the deal structure that deserve a closer look.
Three ASCO readouts, three announcements that claimed more than the data supported — and one question the conference floor has been too busy to ask.
For the first time in ASCO's history, China-only data occupies the plenary slot. A hazard ratio of 0.40 in pancreatic cancer. And Lilly moving the obesity ceiling above bariatric surgery. Chicago has a lot to answer for this week.
